Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BSX stock price vs CGC: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CGC's multiple
Needs CGC P/E.
Implied fair value · at BSX's multiple
Needs EPS (TTM), BSX P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BSX FY 2025 (ended Dec 31, 2025) · CGC FY 2026 (ended Mar 31, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 86% equity / 14% debt · EV / Revenue 3.92x · EV / EBITDA 14.53x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BOSTON SCIENTIFIC CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Canopy Growth Corp · implied price per share
The ordinary-share to listed-security ratio could not be verified.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.47x
0.36x
Net debt / EBITDA
Leverage against operating earnings
1.75x
0.72x
Cash and equivalents
Liquid reserves on the balance sheet
$1.97B
$364.68M
Total debt
Interest-bearing obligations outstanding
$11.44B
$249.60M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Abbott Laboratories
BSX vs ABT
Johnson & Johnson
BSX vs JNJ
Intuitive Surgical, Inc.
BSX vs ISRG
STRYKER CORP
BSX vs SYK
ZIMMER BIOMET HOLDINGS, INC.
BSX vs ZBH
Edwards Lifesciences Corp
BSX vs EW
Tilray Brands, Inc.
BSX vs TLRY
Cronos Group Inc.
BSX vs CRON
AURORA CANNABIS INC
BSX vs ACB
SNDL Inc.
BSX vs SNDL
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
